Tags

Type your tag names separated by a space and hit enter

Osteoporosis in systemic lupus erythematosus: prevention and treatment.
Lupus 2001; 10(3):227-32L

Abstract

The patient with systemic lupus erythematosus (SLE) is at risk of osteoporosis through several factors: the inflammatory disease itself, disease-related co-morbidity, and its treatment. Bone loss is apparent early in the disease and this may be confounded primarily by treatment with corticosteroids. Patients should be assessed for additional risk factors for osteoporosis and general lifestyle measures adopted. Bone mineral density measurement should be considered in SLE patients at high risk of osteoporosis, particularly those starting corticosteroids and in postmenopausal women. Calcium and vitamin D supplementation provide general prophylaxis and are a suitable first-line option. Hormone replacement should be used in hypogondal subjects unless contra-indicated. In subjects at high fracture risk, particularly in postmenopausal women, bisphosphonate therapy should be considered as these agents have been shown to significantly reduce vertebral fracture risk. These measures should reduce the burden of osteoporosis and fracture in patients with lupus.

Authors+Show Affiliations

Metabolic Bone Disease Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, HA7 4LP, UK.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11315358

Citation

Sen, D, and R W. Keen. "Osteoporosis in Systemic Lupus Erythematosus: Prevention and Treatment." Lupus, vol. 10, no. 3, 2001, pp. 227-32.
Sen D, Keen RW. Osteoporosis in systemic lupus erythematosus: prevention and treatment. Lupus. 2001;10(3):227-32.
Sen, D., & Keen, R. W. (2001). Osteoporosis in systemic lupus erythematosus: prevention and treatment. Lupus, 10(3), pp. 227-32.
Sen D, Keen RW. Osteoporosis in Systemic Lupus Erythematosus: Prevention and Treatment. Lupus. 2001;10(3):227-32. PubMed PMID: 11315358.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Osteoporosis in systemic lupus erythematosus: prevention and treatment. AU - Sen,D, AU - Keen,R W, PY - 2001/4/24/pubmed PY - 2001/8/24/medline PY - 2001/4/24/entrez SP - 227 EP - 32 JF - Lupus JO - Lupus VL - 10 IS - 3 N2 - The patient with systemic lupus erythematosus (SLE) is at risk of osteoporosis through several factors: the inflammatory disease itself, disease-related co-morbidity, and its treatment. Bone loss is apparent early in the disease and this may be confounded primarily by treatment with corticosteroids. Patients should be assessed for additional risk factors for osteoporosis and general lifestyle measures adopted. Bone mineral density measurement should be considered in SLE patients at high risk of osteoporosis, particularly those starting corticosteroids and in postmenopausal women. Calcium and vitamin D supplementation provide general prophylaxis and are a suitable first-line option. Hormone replacement should be used in hypogondal subjects unless contra-indicated. In subjects at high fracture risk, particularly in postmenopausal women, bisphosphonate therapy should be considered as these agents have been shown to significantly reduce vertebral fracture risk. These measures should reduce the burden of osteoporosis and fracture in patients with lupus. SN - 0961-2033 UR - https://www.unboundmedicine.com/medline/citation/11315358/Osteoporosis_in_systemic_lupus_erythematosus:_prevention_and_treatment_ L2 - http://journals.sagepub.com/doi/full/10.1191/096120301671413439?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -